Last reviewed · How we verify
Thiazide Candesartan
At a glance
| Generic name | Thiazide Candesartan |
|---|---|
| Sponsor | Institut de Recherches Cliniques de Montreal |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)
- A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 (PHASE1)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide (PHASE3)
- Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |